Comparative Pharmacology
Head-to-head clinical analysis: CAPTOPRIL versus PRINZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPTOPRIL versus PRINZIDE.
CAPTOPRIL vs PRINZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion.
PRINZIDE is a combination of lisinopril (an ACE inhibitor) and hydrochlorothiazide (a thiazide diuretic). Lisinopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume.
Initial: 25 mg PO 2-3 times daily; target dose: 50 mg PO 2-3 times daily; maximum: 450 mg/day. For heart failure: start 6.25-12.5 mg PO 3 times daily, titrate to 25-50 mg PO 3 times daily.
Oral, 1-2 tablets daily; each tablet contains 25 mg hydrochlorothiazide and 5 mg lisinopril. Adjust based on blood pressure response; maximum daily dose: 2 tablets.
None Documented
None Documented
Clinical Note
moderateCaptopril + Benzydamine
"The risk or severity of adverse effects can be increased when Captopril is combined with Benzydamine."
Clinical Note
moderateCaptopril + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Captopril."
Clinical Note
moderateCaptopril + Droxicam
"The risk or severity of adverse effects can be increased when Captopril is combined with Droxicam."
Clinical Note
moderateCaptopril + Loxoprofen
Terminal half-life 1.9 hours, prolonged to 3.5-32 hours in renal impairment; clinical context: requires adjusted dosing in renal failure
Lisinopril: terminal half-life 12 hours (effective half-life 30 hours due to prolonged ACE binding). Hydrochlorothiazide: terminal half-life 6-15 hours (biphasic, initial phase 2-4 h, terminal phase 6-15 h) with prolonged terminal phase in renal impairment.
Primarily renal (50-60% unchanged), with minor biliary/fecal elimination (<5%)
Lisinopril is excreted unchanged in urine (100% renal elimination); hydrochlorothiazide is excreted 95% renally as unchanged drug and 5% via bile.
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor / Diuretic Combination
"The risk or severity of adverse effects can be increased when Captopril is combined with Loxoprofen."